News & Updates
Showing Multidisciplinary articles
Showing

OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.

Dietary modification ups glaucoma risk in women
Dietary modification (DM) among individuals in the lowest quartile for percentage calories from total fat at baseline is associated with a higher risk of incident primary open-angle glaucoma (POAG) among women, irrespective of age or race, suggests a recent study.

What is the best predictor of glucose metabolism deterioration after bariatric surgery?
Weight regain measured as percentage of maximum weight lost (%MWL) appears to be a better predictor of postoperative glucose metabolism deterioration within 3 years than other quantifiers in patients with obesity and type 2 diabetes mellitus (T2DM) who underwent bariatric surgery, according to a China study. Of note, the optimal cutoff point is 20 percent MWL.





